A5017574923- Head and Neck Cancer Studies
- Cancer survivorship and care
- Head and Neck Surgical Oncology
- Salivary Gland Tumors Diagnosis and Treatment
- Oral health in cancer treatment
- Ear and Head Tumors
- Colorectal and Anal Carcinomas
- Cancer Immunotherapy and Biomarkers
- Brain Metastases and Treatment
- Cancer-related cognitive impairment studies
- Frailty in Older Adults
- Inflammatory Biomarkers in Disease Prognosis
- Childhood Cancer Survivors' Quality of Life
- Nutrition and Health in Aging
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Dysphagia Assessment and Management
- Pain Management and Opioid Use
- Palliative Care and End-of-Life Issues
- Health and Wellbeing Research
- Acute Myeloid Leukemia Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cardiac, Anesthesia and Surgical Outcomes
- Nausea and vomiting management
- Family and Patient Care in Intensive Care Units
Centre François Baclesse
2017-2025
Centre François Baclesse
2020-2022
TPEx regimen (docetaxel, platinum, cetuximab) is a first-line treatment option for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) if combined positive score <1, or in case of high tumor burden. We sought to evaluate the survival rates patients receiving real life as R/M HNSCC, particularly since advent immunotherapy (IO) second-line therapy. This multicentric retrospective study included treated by first cycle between 2018 2023, with performance status 0 1. The...
Salivary carcinomas of the tongue represent a therapeutic challenge as their radical excision is particularly mutilating. We aimed to study oncologic and functional outcomes advanced stages salivary tongue. This retrospective multicentric study, based on French national network rare head neck cancers (REFCOR), included all patients with T3-T4 carcinoma tongue, diagnosed between January 2009 December 2018. In total, 47 were included, which 44.7 % underwent surgery. Histologies mostly adenoid...
6036 Background: Salvage chemotherapy after progression on immune checkpoint inhibitors (ICIs) was associated with an objective response rate (ORR) of 30% in patients (pts) recurrent/metastatic squamous cell carcinoma the head and neck (R/M SCCHN). We aimed to investigate efficacy taxanes + cetuximab (TC) +/- platinum pts R/M SCCHN who failed ICIs palliative setting. Methods: A retrospective study conducted at 7 French university hospitals. Eligibility criteria were treated ICI for SCCHN,...